|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Acumen Pharmaceuticals Inc.
| | | Phone: | (925) 368-8508 | Fax: | (925) 605-3813 | Year Established: | 1996 | Main Contact: | William F. Goure, COO | | Other Contacts: | Daniel J. O'Connell, President & CEO
| |
| Company Description | Acumen Pharmaceuticals is a leader in the discovery and development of drugs that block the detrimental effects of soluble oligomers of the amyloid-beta peptide in Alzheimer’s disease. In 2011, Acumen reacquired ACU-193, back-up drug development candidates, a companion diagnostic biomarker, and substantial IP from Merck. Acumen holds IP and know-how for drug discovery approaches other than antibodies and in 2009 licensed its small molecule assembly blocker program to Merz Pharmaceuticals GmbH. | |
|
|
|
|
|